Irina Kryachok’s research while affiliated with National Cancer Institute Ukraine and other places

... 24 , 47 , 64 , 66 , 71 , 87-90 Particularly for primary mediastinal B-cell lymphoma (PMBCL), recent studies suggest that RT may not be necessary for patients who achieve CMR. [87][88][89][90] Importantly, it is often observed that the PFS rates for these PMBCL patients exceed 90%. Based on these findings, an RT benefit in patients with unfavorable prognoses (PFS ≤ 80%) requires urgent confirmation in RCTs. ...

Reference:

Association of overall survival benefit of radiotherapy with progression-free survival after chemotherapy for intermediate and high risk diffuse large B-cell lymphoma: A systematic review and meta-analysis

... In a study of 268 patients with CMR (complete metabolic response) -defined as a Deauville score of 1 to 3 according to the Lugano classification -after treatment with rituximab and anthracycline-based therapy, and who were randomized to either OBS (observation) (n = 132) or RT (n = 136), PFS at 30 months was 96.2% vs. 98.5%. The 5-year overall survival was 99% in both arms [37]. ...

Reference:

Current knowledge and management of primary mediastinal large B-cell lymphoma

... Thus, RT in EoT-PETnegative patients after R-da-EPOCH is clearly clinically irrelevant with a number need-to-treat of 51. These findings are in line with the recent International Extranodal Lymphoma Study Group (IELSG)-37 study, 20 validate the original R-da-EPOCH dataset, 7 and suggest that the omission of RT remains valid even if the strict escalation process is violated in a sizeable minority of them, as often seen in real-life. 13 Patients with D5PSS-4 EoT-PET were not irradiated in the combined NCI/Stanford series with only 1 of 17 progressing and successfully salvaged with resection alone. ...

Reference:

PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?

... Additionally, there are conflicting findings across different datasets regarding the predictive power of TMTV [18,19] and SUVmax [20,21]. Ceriani et al. [22] showed that glucose consumption via Total Lesion Glycolysis (TLG) and Metabolic Heterogeneity (MH) demonstrated superior accuracy in identifying high-risk patients prone to disease progression. There are a number of studies that investigated the feasibility of employing PET "radiomics", to predict treatment outcomes in PMBCL patients [3]. ...

Reference:

Evaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma

... 15 Many South American nations, including Uruguay and Argentina, have recognised the importance of multidisciplinary care for patients with brain tumours, and have invested in and incorporated neuro-oncology multidisciplinary teams (MDTs) comprising neurosurgeons, radiation oncologists, and medical oncologists into mainstream neurosurgical practice. 15,17,18 Also, the availability and access to advanced imaging techniques such as positron emission tomography-computed tomography (PET-CT) has also widely increased, aiding in accurate diagnosis and treatment planning. 18 In addition, there has been a massive increase in the number of dedicated neuro-oncology centres, and to some degree, increased investment into neurosurgical training, and a consequent increase in the number of neurosurgical staff. ...

Reference:

Awake Craniotomies in South America: Advancements, Challenges, and Future Prospects

... Annual open meetings, usually conducted in conjunction with the national haematology scientific congresses, or virtually in 2020-21, provide opportunities for clinicians, site staff, industry partners and students to learn more about the registry. Scientific results are presented at local and international conferences and published in the peer-reviewed literature [10][11][12][13]. Commissioned reports are also provided to industry partners and may be requested by others (for example, government agencies). ...

Reference:

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

... shown in a randomized fashion and such comparisons suffer from important limitations (18)(19)(20)(21). ...

Reference:

Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma

... Current guidelines do not recommend standard endoscopy in the work-up of mantle cell lymphomas. In previous studies it was demonstrated however that PET-CT has a low sensitivity for gastro-intestinal involvement (13,14). Patients can however be asymptomatic and yet they seem to have a worse prognosis. ...

Reference:

Endoscopic diagnosis of a colonic localisation of a mantle cell lymphoma

... With the progressive understanding of the molecular mechanisms of myeloma, numerous innovative drugs have been studied in RRMM patients, such as BCMA ADC belantamab, 23 the XPO-1 inhibitor selinexor, 24,25 a BRAF/MEK co-inhibitor, 26 and the Bcl-2 inhibitor venetoclax, 27 as reported this year. Venetoclax is a well-studied drug, which shows excellent superiority in patients with t (11; 14). ...

Reference:

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020

... In 2020, of 32 abstracts that included at least one aspect of the geriatric assessment in patients with haematological malignancies presented at the annual American Society of Hematology and European Haematology Association meetings, only three included data from LMICs: one from Peru and two multicentre international clinical trials with patients from Brazil and Ukraine. [66][67][68][69][70][71] ...

Reference:

Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings